Licensing
ORx Pharmaxeutical Business Strategy
ORx’s business strategy is to encourage widespread use of its innovations in the pharmaceutical, biopharmaceutical and biotechnology industries by selective licensing of its intellectual property and products. Our business focus is to create value in the product candidates while offering selective access to our intellectual property through patented formulations and new clinical indications. Our licensing regimes offer the following opportunities:
Product Life Cycle Management
Improvements to existing patented therapeutic drugs through the licensed use of ORx’s technology can provide a plausible life cycle extension model for those branded products nearing their exclusivity or patent expiration. A new formulation offering improved clinical benefits and/ or patient compliance can extend the market exclusivity of patented therapeutic drugs beyond the current expiration term.
New Chemical Entity
ORx’s technology solution provides a complementary solution to new chemical entities that are limited by oral bioavailability challenges. Through is effective use ORx’s technology solution can provide a strategy for reducing R&D drop-outs of otherwise promising therapeutic compounds as well as provide a new oral route of administration for those compounds that have defaulted to the parenteral route.
Improved Generics
ORx’s proprietary oral drug delivery technology platform also allows for the development of improved formulations of generic pharmaceuticals, focusing on products that have already received regulatory approval and have achieved substantial sales and marketing success in North America and worldwide. The Company’s strategy is to introduce significant clinical advantage and substantial product differentiation sufficient to create new drug product status and market exclusivity.